[
  {
    "ts": null,
    "headline": "Corcept Submits Application for Another Cushing's Syndrome Drug",
    "summary": "CORT makes pipeline progress with the submission of a new drug application for relacorilant to treat patients with endogenous hypercortisolism.",
    "url": "https://finnhub.io/api/news?id=0eb72454e23d5c31f7d3d55022ecac60352de00944071309b1704eeeaf60254d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735670400,
      "headline": "Corcept Submits Application for Another Cushing's Syndrome Drug",
      "id": 132220881,
      "image": "https://media.zenfs.com/en/zacks.com/59b208c03ab625710a229f805a232093",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "CORT makes pipeline progress with the submission of a new drug application for relacorilant to treat patients with endogenous hypercortisolism.",
      "url": "https://finnhub.io/api/news?id=0eb72454e23d5c31f7d3d55022ecac60352de00944071309b1704eeeaf60254d"
    }
  },
  {
    "ts": null,
    "headline": "Is Bristol-Myers Squibb Company (BMY) Among the Best Pharma Dividend Stocks to Buy In 2024?",
    "summary": "We recently compiled a list of the 13 Best Pharma Dividend Stocks To Buy In 2024. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against the other pharma dividend stocks. The pharmaceutical industry in 2024 faced a relatively quiet year, with deal volumes similar to 2023 but […]",
    "url": "https://finnhub.io/api/news?id=640c0e4243a356685b5c807b67c3ea31d62d3b0e266ed836f786e4c35e42622d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735668858,
      "headline": "Is Bristol-Myers Squibb Company (BMY) Among the Best Pharma Dividend Stocks to Buy In 2024?",
      "id": 132217066,
      "image": "https://s.yimg.com/ny/api/res/1.2/ZsrqNB_sdV78LPtS9DZ12A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/4da437b7638100421dc4d0ddd5060036",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "We recently compiled a list of the 13 Best Pharma Dividend Stocks To Buy In 2024. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against the other pharma dividend stocks. The pharmaceutical industry in 2024 faced a relatively quiet year, with deal volumes similar to 2023 but […]",
      "url": "https://finnhub.io/api/news?id=640c0e4243a356685b5c807b67c3ea31d62d3b0e266ed836f786e4c35e42622d"
    }
  },
  {
    "ts": null,
    "headline": "Is Trending Stock Bristol Myers Squibb Company (BMY) a Buy Now?",
    "summary": "Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=637f26deecbe58f5b7d0097c8fb37715e97c3ed36e3a6463faf50ebed62c0a00",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735653616,
      "headline": "Is Trending Stock Bristol Myers Squibb Company (BMY) a Buy Now?",
      "id": 132217067,
      "image": "https://media.zenfs.com/en/zacks.com/3496571a811465d910e99bd171c71a94",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=637f26deecbe58f5b7d0097c8fb37715e97c3ed36e3a6463faf50ebed62c0a00"
    }
  },
  {
    "ts": null,
    "headline": "Cytokinetics Aligns For U.S. Launch Amid HCM Market Evolution",
    "summary": "Cytokinetics is advancing aficamten, a potential competitor to Camzyos, targeting hypertrophic cardiomyopathy. Read my CYTK stock thesis here.",
    "url": "https://finnhub.io/api/news?id=4ce5ebbbb619aa52af8b4d7ce31dc1f01f83a1a3ae56babbf3406f530ef68117",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735633800,
      "headline": "Cytokinetics Aligns For U.S. Launch Amid HCM Market Evolution",
      "id": 132213909,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1158389594/image_1158389594.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Cytokinetics is advancing aficamten, a potential competitor to Camzyos, targeting hypertrophic cardiomyopathy. Read my CYTK stock thesis here.",
      "url": "https://finnhub.io/api/news?id=4ce5ebbbb619aa52af8b4d7ce31dc1f01f83a1a3ae56babbf3406f530ef68117"
    }
  },
  {
    "ts": null,
    "headline": "Halozyme: Recent Approvals Alter My Appetite",
    "summary": "Halozyme's attempt to acquire Evotec was a bold move to diversify revenue, but was ultimately unsuccessful, impacting HALO's stock price. Read more here.",
    "url": "https://finnhub.io/api/news?id=c714bfa806708643506ee41b5cea12f5daccff8dfa36735e7e106da9f2c9de6f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735612879,
      "headline": "Halozyme: Recent Approvals Alter My Appetite",
      "id": 132210479,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/904136898/image_904136898.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Halozyme's attempt to acquire Evotec was a bold move to diversify revenue, but was ultimately unsuccessful, impacting HALO's stock price. Read more here.",
      "url": "https://finnhub.io/api/news?id=c714bfa806708643506ee41b5cea12f5daccff8dfa36735e7e106da9f2c9de6f"
    }
  }
]